Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2017 Aug 25;7(8):e597. doi: 10.1038/bcj.2017.77

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Risk of progression from MBL to CLL or other CLPDs. (a) Time-to-progression according to the phenotypic category. (b–d) Progression-free survival according to absolute B-cell count for CLL-like (b), atypical (c) and CD5^neg (d) MBL. (e) Progression-free survival according to the presence of clonal evolution. (f) Progression-free survival for CLL-like MBL subjects with 2000–3900 B-cell count at initial diagnosis according to the presence or absence of clonal evolution. (g) Treatment-free survival for progressed cases according to the presence of clonal evolution at the preclinical MBL stage. CLPD, chronic lymphoproliferative disorder.